Redefining the therapeutic goals in chronic lymphocytic leukemia: Towards an evidence-based, risk-adapted therapy

CM Wendtner; B Schmitt; Martin Wilhelm; P Dreger; E Montserrat; B Emmerich; M Hallek

doi:10.1023/A:1026481430446

Redefining the therapeutic goals in chronic lymphocytic leukemia: Towards an evidence-based, risk-adapted therapy

CM Wendtner, B Schmitt, Martin Wilhelm (Co-author), P Dreger, E Montserrat, B Emmerich, M Hallek

Research output: Contribution to journal › Short comment / notes › peer-review

10 Citations (Web of Science)

Original language	English
Pages (from-to)	505-509
Journal	ANNALS OF ONCOLOGY
Volume	10
Issue number	5
DOIs	https://doi.org/10.1023/A:1026481430446
Publication status	Published - 1999

Keywords

MALIGNANCIES
CELLS
FLAVOPIRIDOL
APOPTOSIS
INHIBITOR
DISEASE

Access to Document

10.1023/A:1026481430446

Cite this

Wendtner, CM., Schmitt, B., Wilhelm, M., Dreger, P., Montserrat, E., Emmerich, B., & Hallek, M. (1999). Redefining the therapeutic goals in chronic lymphocytic leukemia: Towards an evidence-based, risk-adapted therapy. ANNALS OF ONCOLOGY , 10(5), 505-509. https://doi.org/10.1023/A:1026481430446

Wendtner, CM ; Schmitt, B ; Wilhelm, Martin et al. / Redefining the therapeutic goals in chronic lymphocytic leukemia: Towards an evidence-based, risk-adapted therapy. In: ANNALS OF ONCOLOGY 1999 ; Vol. 10, No. 5. pp. 505-509.

@article{440c10f1a1944dbbbcd8a691d77aea3d,

title = "Redefining the therapeutic goals in chronic lymphocytic leukemia: Towards an evidence-based, risk-adapted therapy",

keywords = "MALIGNANCIES, CELLS, FLAVOPIRIDOL, APOPTOSIS, INHIBITOR, DISEASE",

author = "CM Wendtner and B Schmitt and Martin Wilhelm and P Dreger and E Montserrat and B Emmerich and M Hallek",

year = "1999",

doi = "10.1023/A:1026481430446",

language = "English",

volume = "10",

pages = "505--509",

journal = "ANNALS OF ONCOLOGY ",

issn = "0923-7534",

publisher = "Elsevier ",

number = "5",

}

Wendtner, CM, Schmitt, B, Wilhelm, M, Dreger, P, Montserrat, E, Emmerich, B & Hallek, M 1999, 'Redefining the therapeutic goals in chronic lymphocytic leukemia: Towards an evidence-based, risk-adapted therapy', ANNALS OF ONCOLOGY , vol. 10, no. 5, pp. 505-509. https://doi.org/10.1023/A:1026481430446

Redefining the therapeutic goals in chronic lymphocytic leukemia: Towards an evidence-based, risk-adapted therapy. / Wendtner, CM; Schmitt, B; Wilhelm, Martin (Co-author) et al.
In: ANNALS OF ONCOLOGY , Vol. 10, No. 5, 1999, p. 505-509.

Research output: Contribution to journal › Short comment / notes › peer-review

TY - JOUR

T1 - Redefining the therapeutic goals in chronic lymphocytic leukemia: Towards an evidence-based, risk-adapted therapy

AU - Wendtner, CM

AU - Schmitt, B

AU - Wilhelm, Martin

AU - Dreger, P

AU - Montserrat, E

AU - Emmerich, B

AU - Hallek, M

PY - 1999

Y1 - 1999

KW - MALIGNANCIES

KW - CELLS

KW - FLAVOPIRIDOL

KW - APOPTOSIS

KW - INHIBITOR

KW - DISEASE

U2 - 10.1023/A:1026481430446

DO - 10.1023/A:1026481430446

M3 - Short comment / notes

C2 - 10415998

SN - 0923-7534

VL - 10

SP - 505

EP - 509

JO - ANNALS OF ONCOLOGY

JF - ANNALS OF ONCOLOGY

IS - 5

ER -

Wendtner CM, Schmitt B, Wilhelm M, Dreger P, Montserrat E, Emmerich B et al. Redefining the therapeutic goals in chronic lymphocytic leukemia: Towards an evidence-based, risk-adapted therapy. ANNALS OF ONCOLOGY . 1999;10(5):505-509. doi: 10.1023/A:1026481430446